Matinèe - A multi-center, randomized, double-blind, parallel-group, placebo controlled study of mepolizumab 100 mg SC as add-on treatment in participants with COPD experiencing frequent exacerbations and characterized by eosinophil levels

Obiettivi del progetto

Primary • To evaluate the efficacy of mepolizumab 100 mg subcutaneous (SC) compared to placebo, given every 4 weeks in liquid formulation by safety syringe (SS) to COPD participants at high risk of exacerbations despite the use of optimized COPD maintenance therapy.

Secondary • To evaluate mepolizumab 100 mg SC compared to placebo given every 4 weeks in liquid formulation by SS on additional efficacy assessments, health related quality of life (HRQoL), health care utilization, and symptoms.

Data di inizio e fine

Responsabile del progetto

Istituzione coordinatrice del progetto

Altre Istituzioni coinvolte

• Studio Multicentrico internazionale

Fonte/i di finanziamento